The JUPITER Results: Will The Planets Align For OTC Statins? AstraZeneca's JUPITER trial onCrestor (rosuvastatin) greatly expands the pool of patients who may benefit from statin use, which could help make the case for an OTC switch in the cholesterol-lowering class in the future. READ MORE>>
Zyrtec OTC Launch Does Not Deliver Knockout To Rx Remedies – Report Fewer consumers than expected have switched from Rx products to OTC Zyrtec in part because managed care organizations are not discouraging use of prescription allergy medications, according to research by Nielsen and Wolters Kluwer Health. READ MORE>>